Clinical relevance of genetic polymorphism in the CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: Validatory pharmacogenomic approach to pharmacovigilance

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 7, 2015, Pages 504-516

  Kousar, Shazia ^a   Wafai, Zahoor A ^a   Wani, Mushtaq A ^a   Jan, Tariq R ^b   Andrabi, Khurshid I ^b  

^a SHER I KASHMIR INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF KASHMIR   (India)

Author keywords

ADR causality assessment; CYP2C9 gene; Epilepsy; Kashmir; Pharmacogenomics; Phenytoin

Indexed keywords

CYTOCHROME P450 2C9; PHENYTOIN; ANTICONVULSIVE AGENT; CYP2C9 PROTEIN, HUMAN;

ADULT; ALLELE; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; CONTROLLED STUDY; CYP2C9 GENE; DENTAL CARIES; DIZZINESS; DRUG BLOOD LEVEL; DRUG RESPONSE; DRUG SURVEILLANCE PROGRAM; ELECTROPHORESIS; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; EPIGASTRIC PAIN; EPILEPSY; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENERALIZED EPILEPSY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GINGIVA BLEEDING; GINGIVA HYPERTROPHY; HEADACHE; HEART PALPITATION; HUMAN; INDIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MEASLES LIKE RASH; MEMORY DISORDER; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHARMACOGENOMICS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SOMNOLENCE; TOOTH PAIN; TREMOR; UNSTEADY GAIT; WEAKNESS; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA; BIOTRANSFORMATION; CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETICS; METABOLIC CLEARANCE RATE; METABOLISM; PHARMACOGENETICS; PHENOTYPE; VALIDATION STUDY;

ANTICONVULSANTS; AREA UNDER CURVE; BIOTRANSFORMATION; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2C9; EPILEPSY; GENE FREQUENCY; GENOTYPE; HUMANS; INDIA; METABOLIC CLEARANCE RATE; PHARMACOGENETICS; PHARMACOVIGILANCE; PHENOTYPE; PHENYTOIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 84936742187     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202112     Document Type: Article

References (45)

1. Weinshilboum R. Pharmacogenetics and Pharmacogenomics. In: Scott. A Waldman AT: Pharmacology and Therapeutics: principles to practice. Ist edn: Saunders Elsevier 1600 John F Kennedy Blvd. Site 1800 Philadelphia, PA 19103-2899; 2008.
2. Leslie J. Sheffield HEP. Clinical Use of Pharmacogenomic Tests in 2009. Clin Biochem Rev. 2009; 30: 10.
3. Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia. 2009; 50: 1-23. CrossRef PubMed
4. Rosemary J, Surendiran A, Rajan S, Shashindran CH, Adithan C. Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India. Indian J Med Res. 2006; 123: 665-670. PubMed
5. Sadhu KK. Bio-demographic study of Kashmiris. Delhi, India: Gian Pub. House; 1987.
6. Kashmiri food http://www.jammu.com/kashmir/kashmiri-food.htm.
7. Where is Kashmir located in longitude and latitude? http://wiki.answers.com/Q/Where-is-Kashmir-located-in-longitude-and-latitude.
8. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 1996; 6: 341-349. CrossRef PubMed
9. Teuscher lcc-a-l-a-l-lN. Calculating AUC (linear and log-linear). April 2, 2011.
10. Mamiya K, Ieiri I, Shimamoto J, Yukawa E, Imai J, Ninomiya H, Yamada H, Otsubo K, Higuchi S, Tashiro N. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia. 1998; 39: 1317-1323. CrossRef PubMed
11. Wang SL, Huang J, Lai MD, Tsai JJ. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics. 1995; 5: 37-42. CrossRef PubMed
12. Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, Cha IJ, Shin JG. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol. 2001; 51: 277-280. CrossRef PubMed
13. Rosemary J, Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr Clin Pharmacol. 2007; 2: 93-109. CrossRef PubMed
14. http://en.wikipedia.org/wiki/CYP2C9. Allele frequencies(%) of CYP2C9 polymorphism.
15. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev. 2002; 54: 1257-1270. CrossRef PubMed
16. Lakhan R, Kumari R, Singh K, Kalita J, Misra UK, Mittal B. Possible role of CYP2C9 & CY-P2C19 single nucleotide polymorphisms in drug refractory epilepsy. Indian J Med Res. 2011; 134: 295-301. PubMed
17. Kumari R, Lakhan R, Garg RK, Kalita J, Misra UK, Mittal B. Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population. Indian J Hum Genet. 2011; 17 (Suppl 1): S32-S40. PubMed
18. Twardowschy CA, Werneck LC, Scola RH, De Paola L, Silvado CE. CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes and phenytoin adverse reactions correlation. Arq Neuropsiquiatr. 2011; 69 (2A): 153-158. PubMed
19. CHEN JJ. The Hardy-Weinberg Principle and its application in modern population genetics. Front Biol. 2010; 5: 348-353.
20. Ashraf M. Burzahom and the origin of Kashmiris. 2007.
21. Sebro R, Lange C, Laird NM, Rogus JJ, Risch NJ. Differentiating population stratification from genotyping error using family data. Ann Hum Genet. 2012; 76: 42-52. CrossRef PubMed
22. Nachman MW, Crowell SL. Estimate of the mutation rate per nucleotide in humans. Genetics. 2000; 156: 297-304. PubMed
23. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet. 2005; 76: 887-893. CrossRef PubMed
24. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 2001; 11: 803-808. CrossRef PubMed
25. Ramasamy K, Narayan SK, Chanolean S, Chandrasekaran A. Severe phenytoin toxicity in a CYP2C9∗3∗3 homozygous mutant from India. Neurol India. 2007; 55: 408-409. CrossRef PubMed
26. Aynacioglu AS, Brockmöller J, Bauer S, Sachse C, Güzelbey P, Ongen Z, Nacak M, Roots I. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol. 1999; 48: 409-415. CrossRef PubMed
27. Kerb R, Aynacioglu AS, Brockmöller J, Schlagenhaufer R, Bauer S, Szekeres T, Hamwi A, Fritzer-Szekeres M, Baumgartner C, Ongen HZ, Güzelbey P, Roots I, Brinkmann U. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J. 2001; 1: 204-210. CrossRef PubMed
28. Huang Y YJ, Qi XL, Wang YQ, Wang WZ, Chen B. Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration. Zhonghua Yi Xue Za Zhi. 2004; 84: 1686-1689. PubMed
29. Odani A, Hashimoto Y, Otsuki Y, Uwai Y, Hattori H, Furusho K, Inui K. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther. 1997; 62: 287-292. CrossRef PubMed
30. Shon JH, Yoon YR, Kim KA, Lim YC, Lee KJ, Park JY, Cha IJ, Flockhart DA, Shin JG. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics. 2002; 12: 111-119. CrossRef PubMed
31. Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb Res. 2007; 120: 1-10. CrossRef PubMed
32. Daly AK, Day CP, Aithal GP. CYP2C9 polymorphism and warfarin dose requirements. Br J Clin Pharmacol. 2002; 53: 408-409. CrossRef PubMed
33. Vianna-Jorge R, Perini JA, Rondinelli E, Suarez-Kurtz G. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin Pharmacol Ther. 2004; 76: 18-26. CrossRef PubMed
34. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002; 12: 251-263. CrossRef PubMed
35. Depondt C, Godard P, Espel RS, Da Cruz AL, Lienard P, Pandolfo M. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity. Eur J Neurol. 2011; 18: 1159-1164. Cross-Ref PubMed
36. Kesavan R, Narayan SK, Adithan C. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients. Eur J Clin Pharmacol. 2010; 66: 689-696. CrossRef PubMed
37. Soga Y, Nishimura F, Ohtsuka Y, Araki H, Iwamoto Y, Naruishi H, Shiomi N, Kobayashi Y, Takashiba S, Shimizu K, Gomita Y, Oka E. CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects. Life Sci. 2004; 74: 827-834. CrossRef PubMed
38. Lee AY, Kim MJ, Chey WY, Choi J, Kim BG. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions. Eur J Clin Pharmacol. 2004; 60: 155-159. CrossRef PubMed
39. Thakkar AN, Bendkhale SR, Taur SR, Gogtay NJ, Thatte UM. Association of CYP2C9 polymorphisms with phenytoin toxicity in Indian patients. Neurol India. 2012; 60: 577-580. CrossRef PubMed
40. Prasad VN, Chawla HS, Goyal A, Gauba K, Singhi P. Incidence of phenytoin induced gingival overgrowth in epileptic children: a six month evaluation. J Indian Soc Pedod Prev Dent. 2002; 20: 73-80. PubMed
41. http://www.ehealthme.com/ds/dilantin/tremor. dilantin tremor.
42. Sevim Erdem JTK, Mendell Jerry R. Toxic neuropathies: drugs, metals and alcohol. In: Diagnosis and Management of Peripheral Nerve Disorders, Jerry R. Mendell, John T. Kissel, David R. Cornblath (eds). New York: Oxford University press Oxford New York; 2001. p. 314.
43. Shorvon SD, Reynolds EH. Anticonvulsant peripheral neuropathy: a clinical and electrophysiological study of patients on single drug treatment with phenytoin, carbamazepine or barbiturates. J Neurol Neurosurg Psychiatry. 1982; 45: 620-626. CrossRef PubMed
44. Ding WY, Lee CK, Choon SE. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2010; 49: 834-841. PubMed
45. Sudershan V, Siddiqua S, Aruna D, Manmohan, Ramesh S, Nazia Yasmeen. Cutaneous adverse drug reactions in a tertiary care hospital. Der Pharmacia Lettre. 2011; 3: 210-217.